4-氨基-N-(2-甲氧基苯基)-苯甲酰胺 | 787-59-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-氨基-N-(2-甲氧基苯基)-苯甲酰胺
• 英文名称: N-(2-methoxyphenyl)-4-aminobenzamide
• 英文别名: 4-Amino-benz-<2-methoxy-anilid>；4-Amino-benz-(2-methoxy-anilid)；4-amino-N-(2-methoxyphenyl)benzamide
• CAS: 787-59-7
• 化学式: C₁₄H₁₄N₂O₂
• mdl: MFCD00568219
• 分子量: 242.277
• InChiKey: DCVSWMVFHSQIJJ-UHFFFAOYSA-N

物化性质

• 熔点：
  162 °C
• 沸点：
  357.4±27.0 °C(Predicted)
• 密度：
  1.245±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.071
• 拓扑面积：
  64.4
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2924299090

反应信息

• 作为反应物：
  描述：

  4-氨基-N-(2-甲氧基苯基)-苯甲酰胺 在 potassium carbonate 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 生成
  参考文献：
  名称：

  一种噻吩并嘧啶酮化合物及其用途

  摘要：

  本发明属于化学医药领域，具体一种噻吩并嘧啶酮化合物，其结构式为：本发明合成了一种新型噻吩并嘧啶酮化合物，证实了化合物能够对Tankyrase产生较好的抑制作用，无明显的毒性作用，用该化合物处理STF3A细胞后，发现可明显抑制肿瘤细胞增殖，具有很好的药用潜力，为临床用药提供了一种新的潜在选择；该新型噻吩并嘧啶酮化合物能增强wnt信号途径中轴蛋白的表达水平,诱导β‑连环蛋白的降解，从而抑制肿瘤细胞增殖，能够作为多种肿瘤细胞的临床前药候选化合物，具有进一步研究开发的潜力；还提供了该新型噻吩并嘧啶酮化合物，该制备方法能够得到较高产率高生物活性的化合物，该使得该化合物类药性显著，具有广阔的市场前景。

  公开号：

  CN109180702B
• 作为产物：
  描述：

  邻甲氧基苯胺 在 吡啶 、 palladium on activated charcoal 、 氢气 作用下， 以 乙醇 为溶剂， 反应 19.0h， 生成 4-氨基-N-(2-甲氧基苯基)-苯甲酰胺
  参考文献：
  名称：

  Wnt Inhibition Correlates with Human Embryonic Stem Cell Cardiomyogenesis: A Structure–Activity Relationship Study Based on Inhibitors for the Wnt Response

  摘要：

  Human embryonic stem cell-based high-content screening of 550 known signal transduction modulators showed that one "lead" (1, a recently described inhibitor of the proteolytic degradation of Axin) stimulated cardiomyogenesis. Because Axin controls canonical Wnt signaling, we conducted an investigation to determine whether the cardiogenic activity of 1 is Wnt-dependent, and we developed a structure-activity relationship to optimize the cardiogenic properties of 1. We prepared analogues with a range of potencies (low nanomolar to inactive) for Wnt/beta-catenin inhibition and for cardiogenic induction. Both functional activities correlated positively (r(2) = 0.72). The optimal compounds induced cardiogenesis 1.5-fold greater than 1 at 30-fold lower concentrations. In contrast, no correlation was observed for cardiogenesis and modulation of transforming growth factor beta (TGF beta)/Smad signaling that prominently influences cardiogenesis. Taken together, these data show that Wnt signaling inhibition is essential for cardiogenic activity and that the pathway can be targeted for the design of druglike cardiogenic molecules.

  DOI：

  10.1021/jm2010223

文献信息

• WNT INHIBITORS FOR HUMAN STEM CELL DIFFERENTIATION
  申请人：Cashman John

  公开号：US20130177535A1

  公开（公告）日：2013-07-11

  Methods and small molecule compounds for stem cell differentiation and treatment of animals with diseases are provided. One example of a class of compounds that may be used is represented by the compound of Formula I and II: or a pharmaceutically acceptable salt or solvate thereof, wherein A, X, Q, R 1 , R 2 , R 3 , R 4 are as described herein.

  提供了用于干细胞分化和治疗患有疾病的动物的方法和小分子化合物。可以使用的一类化合物的一个示例由式I和II表示： 或其药用可接受的盐或溶剂，其中A、X、Q、R1、R2、R3、R4如本文所述。
• NAPHTHYRIDINONES AS PROTEIN KINASE INHIBITORS
  申请人：Xiao Yufang

  公开号：US20110269758A1

  公开（公告）日：2011-11-03

  Naphthyridinone derivative compounds that inhibit Aurora kinase enzymes are disclosed along with pharmaceutical compositions comprising these compounds and methods for synthesizing the same. Such compounds have utility in the treatment of proliferative diseases resulting from unregulated and/or disturbed Aurora kinases such as cancers, psoriasis, viral and bacterial infections, inflammatory and autoimmune diseases.

  本发明揭示了抑制Aurora激酶酶的萘啶酮衍生物化合物，以及包含这些化合物的制药组合物和合成这些化合物的方法。这些化合物在治疗由未调节和/或扰动的Aurora激酶引起的增殖性疾病中具有实用性，如癌症、银屑病、病毒和细菌感染、炎症性和自身免疫性疾病。
• Development of Novel Dual Binders as Potent, Selective, and Orally Bioavailable Tankyrase Inhibitors
  作者：Zihao Hua、Howard Bregman、John L. Buchanan、Nagasree Chakka、Angel Guzman-Perez、Hakan Gunaydin、Xin Huang、Yan Gu、Virginia Berry、Jingzhou Liu、Yohannes Teffera、Liyue Huang、Bryan Egge、Renee Emkey、Erin L. Mullady、Steve Schneider、Paul S. Andrews、Lisa Acquaviva、Jennifer Dovey、Ankita Mishra、John Newcomb、Douglas Saffran、Randy Serafino、Craig A. Strathdee、Susan M. Turci、Mary Stanton、Cindy Wilson、Erin F. DiMauro

  DOI：10.1021/jm401317z

  日期：2013.12.27

  Tankyrases (TNKS1 and TNKS2) are proteins in the poly ADP-ribose polymerase (PARP) family. They have been shown to directly bind to axin proteins, which negatively regulate the Wnt pathway by promoting β-catenin degradation. Inhibition of tankyrases may offer a novel approach to the treatment of APC-mutant colorectal cancer. Hit compound 8 was identified as an inhibitor of tankyrases through a combination of substructure searching of the Amgen compound collection based on a minimal binding pharmacophore hypothesis and high-throughput screening. Herein we report the structure- and property-based optimization of compound 8 leading to the identification of more potent and selective tankyrase inhibitors 22 and 49 with improved pharmacokinetic properties in rodents, which are well suited as tool compounds for further in vivo validation studies.
• US9023340B2
  申请人：——

  公开号：US9023340B2

  公开（公告）日：2015-05-05
• [EN] NAPHTHYRIDININONES AS AURORA KINASE INHIBITORS<br/>[FR] NAPHTYRIDININONES EN TANT QU'INHIBITEURS D'AURORA KINASE
  申请人：MERCK SERONO SA

  公开号：WO2010002779A2

  公开（公告）日：2010-01-07

  Naphthyridinone derivative compounds that inhibit Aurora kinase enzymes are disclosed along with pharmaceutical compositions comprising these compounds and methods for synthesizing the same. Such compounds have utility in the treatment of proliferative diseases resulting from unregulated and/or disturbed Aurora kinases such as cancers, psoriasis, viral and bacterial infections, inflammatory and autoimmune diseases.